[Current status of therapy of tuberculosis of the mucous membranes of the ENT area, a comparative evaluation of new drugs, streptomycin, PAS, TB1 and isonicotinic acid hydrazide].
D010131:Aminosalicylic Acid / Q000627:therapeutic use*; D004194:Disease; D007538:Isoniazid; D009059:Mouth Diseases; D009092:Mucous Membrane; D009525:Niacin; D009539:Nicotinic Acids / Q000627:therapeutic use*; D014066:Palatine Tonsil; D010608:Pharyngeal Diseases; D010614:Pharynx; D013307:Streptomycin / Q000627:therapeutic use*; D013882:Thiosemicarbazones / Q000627:therapeutic use*; D014376:Tuberculosis / Q000628:therapy*; D014387:Tuberculosis, Laryngeal / Q000628:therapy*
D009539:Nicotinic Acids; D013882:Thiosemicarbazones; D009525:Niacin; D010131:Aminosalicylic Acid; D007538:Isoniazid; D013307:Streptomycin
MOUTH/diseases; NICOTINIC ACID ISOMERS/therapeutic use; PARA-AMINOSALICYLIC ACID/therapeutic use; PHARYNX/diseases; STREPTOMYCIN/therapeutic use; THIOSEMICARBAZONES/therapeutic use; TONSILS/diseases; TUBERCULOSIS, LARYNGEAL/therapy; TUBERCULOSIS/therapy
Estado actual de la terapia de la tuberculosis de las mucosas de la esfera otorrinolaringológica; una evaluación comparativa de las nuevas drogas; estreptomicina, PAS, TB1 e hidrazida del acido isonicotínico.